Skip to content
Accessibility help
Search NICE…
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Deferred
Awaiting development
Topic prioritisation
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (9)
Type
Type
Guidance (354)
Quality standard (29)
Guidance programme
Guidance programme
HealthTech guidance (11)
Technology appraisal guidance (343)
Apply filters
Showing 371 to 380 of 383
Guidance and quality standards awaiting development
Title
Type
WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]
Technology appraisal guidance
Xanomeline tartrate–trospium chloride for treating schizophrenia [TSID12311]
Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]
Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765]
Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477]
Technology appraisal guidance
Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma [ID6672]
Technology appraisal guidance
Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [ID6641]
Technology appraisal guidance
Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]
Technology appraisal guidance
Zavegepant for treating acute migraine [TSID11998]
Technology appraisal guidance
Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]
Technology appraisal guidance
Previous page
1
…
36
37
Current page
38
39
Page
38
of
39
Next page
Results per page
10
25
50
All
Back to top